MSCLFSATELLOS BIOSCIENCE INC.

About SATELLOS BIOSCIENCE INC. (MSCLF)

SATELLOS BIOSCIENCE INC. (MSCLF) is a Biotechnology company headquartered in Toronto, ON, Canada whose shares trade over-the-counter on the OTCQB tier.

Satellos is a publicly traded, clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit www.satellos.com.

Products and services

Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenXTM, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in Toronto, Ontario. For more information, visit www.satellos.com.

MSCLF key facts

Ticker symbol

MSCLF

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Toronto, ON, Canada

Country of incorporation

CA

Year of incorporation

2005

Employees

20

Estimated market cap

$74.60M (as of Apr 11, 2025)

Shares outstanding

165,824,872

Reporting standard

International Reporting: Toronto Stock Exchange

Audit status

Audited

Fiscal year end

12/31

Latest filing

Quarterly Report (Sep 30, 2024)

SATELLOS BIOSCIENCE INC. leadership

• Frank Gleeson — President, CEO
• Elizabeth Williams — CFO
• J. Robert Hall — VP, Fin.
• Deepah Singh — Vice President
• Michael Rudnicki — CSO
• Accounts Payable — Other

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with M